Baltimore-based Agenebio Inc. has enrolled the first patient in a phase III trial of a drug for amnestic mild cognitive impairment (MCI) due to Alzheimer's disease (AD). The medicine, an experimental once-daily, extended-release formulation of the common epilepsy medication levetiracetam, is called AGB-101. It targets the reduction of neuronal overactivity in the hippocampus, thought to drive downstream pathology and memory impairment. The trial, called Hope4MCI, is supported in part by $16 million in grant money from the NIH.